Co-targeting cancer stem-like cells and bulk cancer cells with a bispecific antibody

Area of Science:

• Oncology
• Molecular Biology
• Cancer Therapeutics

Background:

• Epidermal Growth Factor Receptor (EGFR) is a key target in cancer therapy.
• Tumor resistance to EGFR inhibitors and radiation is a significant clinical challenge.
• Cancer stem cells contribute to therapeutic resistance and disease recurrence.

Purpose of the Study:

• To investigate the efficacy of dual targeting of EGFR and NOTCH2/3 receptors.
• To evaluate the anti-stem effects of antibody CT16 in overcoming therapeutic resistance.
• To assess the combined impact of CT16 with standard therapies.

Main Methods:

• In vitro cell culture experiments to assess anti-stem effects.
• In vivo studies in preclinical models to evaluate therapeutic efficacy.
• Analysis of molecular markers associated with EGFR and NOTCH signaling pathways.

Main Results:

• Dual targeting with CT16 exhibited a strong anti-stem effect.
• The antibody CT16 demonstrated efficacy in overcoming resistance to EGFR inhibitors.
• Combined targeting showed significant anti-tumor activity both in vitro and in vivo.

Conclusions:

• Dual inhibition of EGFR and NOTCH2/3 receptors is a promising strategy to overcome tumor resistance.
• Antibody CT16 shows potential as a novel therapeutic agent for resistant cancers.
• Targeting cancer stemness is crucial for improving treatment outcomes in EGFR-driven tumors.